CTLA4 and neoplasm: Moreover, in line with findings from patient case reports and retrospective analyses, research using cancer models in mice have also demonstrated targeting the RANK-RANKL axis in combination with anti-CTLA-4 checkpoint inhibition and showed significant synergistic effects in immune-mediated tumor rejection in multiple tumor types (161, 165, 166).